Calcium absorption and excretion in patients treated with verapamil.
Calcium absorption and excretion in patients treated with verapamil.
复制标题
用维拉帕米治疗的患者的钙吸收和排泄。
DOI：
--
复制
发表时间：
1987
影响因子：
3.4
通讯作者：
K. Haglund
中科院分区：
文献类型：
--
作者：
G. Sjödén;M. Rosenqvist;E. Kriegholm;K. Haglund
1. 采用单同位素技术研究维拉帕米对肠道钙吸收的影响。对9例患者在维拉帕米治疗2个月期间的血钙和尿钙排泄量进行了随访。2. 每次80-120毫克（每日三次）可显著降低收缩压和舒张压。3. 肠道钙吸收率（α）没有变化，以每小时吸收给定活性的分数表示（α = 0.82 +/- 0.19 vs α = 0.83 +/- 0.25; +/- s.d， NS）或尿钙排泄量（钙/肌酐比值0.35 +/- 0.20 vs 0.31 +/- 0.33； NS）。4. 治疗前后血清钙含量差异无统计学意义（2.43 mmol -1 +/- 0.10 vs 2.47 mmol -1 +/- 0.14； NS）。5. 本研究表明，维拉帕米在临床推荐使用的剂量下，似乎不会影响钙的肠道吸收、血清钙浓度或尿中钙的排泄。
1. The effect of verapamil on the intestinal absorption of calcium was studied using a single isotope technique. Serum calcium and urinary excretion of calcium in the urine were followed in nine patients during treatment with verapamil for 2 months. 2. A dose of 80-120 mg (three times daily) resulted in a significant reduction of systolic and diastolic blood pressure. 3. There was no change in the intestinal calcium absorption (alpha) expressed as the fraction of given activity absorbed per hour (alpha = 0.82 +/- 0.19 vs alpha = 0.83 +/- 0.25; +/- s.d., NS) or of the excretion of calcium in urine (Ca/creatinine ratio 0.35 +/- 0.20 vs 0.31 +/- 0.33; NS). 4. Serum calcium was not significantly different before and during treatment (2.43 mmol l-1 +/- 0.10 vs 2.47 mmol l-1 +/- 0.14; NS). 5. This study demonstrates that verapamil, at doses recommended for clinical use, does not seem to affect the intestinal absorption of calcium, the serum calcium concentration or the excretion of calcium in urine.